MRI contrast agent safety in renal impairment

Boyd AS , Zic JA , Abraham JL . Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 27–30

Collidge TA , Thomson PC , Mark PB , Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007; 245: 168–75

Cowper SE , Robin HS , Steinberg SM , Su LD , Gupta S , LeBoit PE . Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000–1

ESUR Contrast Media Safety Committee. ESUR Guidleines on Contrast Media version 6.0. 2007. See http://www.esur.org/ESUR_Guidelines_NEW.6.0.html

Grainger RG , Thomsen HS , Morcos SK , Koh D-M , Roditi G . Intravascular contrast media for radiology, CT and MRI. In: Adam A , Dixon AD , Grainger RG , Allison DJ , eds. Grainger and Allison's Diagnostic Radiology – A Textbook of Medical Imaging. London: Elsevier Churchill Livingstone, 2008: 31–53

Grobner T . Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104–8

Grobner T . Erratum. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1745

Hoffmann U , Fischereder M , Reil A , Fischer M , Link J , Kramer BK . Renal effects of gadopentetate dimeglumine in patients with normal and impaired renal function. Eur J Med Research 2005; 10: 149–54

Kanal E , Barkovich AJ , Bell C , ACR Guidance Document for Safe MR Practices: 2007. AJR 2007; 188: 1–27

Kroencke TJ , Taupitz M , Arnold R , Three-dimensional gadolinium-enhanced magnetic resonance venography in suspected thrombo-occlusive disease of the central chest veins. Chest 2001; 120: 1570–6

Marckmann P , Skov L , Rossen K , Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359–62

Morcos SK . Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008; 66: 175–9

Prince MR , Grist TM , Debatin JF . 3D Contrast MR Angiography. 3rd edn. Berlin: Springer, 2002

Prince MR , Sostman HD . MR venography: unsung and underutilized. Radiology 2003; 226: 630–2

Prince MR , Erel HE , Lent RW , Gadodiamide administration causes spurious hypocalcemia. Radiology 2003; 227: 639–46

Sadowski EA , Bennett LK , Chan MR , Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148–57

Thomsen HS . Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 2004; 14: 1654–6

Thomsen HS , Marckmann P . Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 2008; 66: 180–3

Tombach B , Bremer C , Reimer P , Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 2001; 218: 651–7

Tombach B , Bremer C , Reimer P , Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol 2002; 178: 105–9